Conversion of amides and lactams to thioamides and thiolactams using hexamethyldisilathiane
摘要:
Amides and lactams were converted to their corresponding thioamides and thiolactams employing a new protocol using hexamethyldisilathiane (TMS(2)S). Oxophilic promoters were employed to generate Vilsmeier-type intermediates, the most efficient reagents being phosphorus oxychloride, triphosgene, and oxalyl chloride. Thionation of intermediate chloro iminium ions was accomplished in situ with TMS(2)S. Yields were good to excellent for secondary and tertiary amides and lactams while yields for primary systems were poor.
2-Amino-quinazolin-5-one compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cell proliferative diseases.
New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
The present invention provides a compound of formula (I):
and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.
[EN] PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS PHÉNYL-HÉTÉROARYL AMINE ET LEURS UTILISATIONS
申请人:NOVARTIS AG
公开号:WO2012066065A1
公开(公告)日:2012-05-24
The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
[EN] SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES<br/>[FR] COMPOSÉS BI-HÉTÉROARYLES SUBSTITUÉS EN TANT QU'INHIBITEURS DE CDK9 ET LEURS UTILISATIONS
申请人:NOVARTIS AG
公开号:WO2012101062A1
公开(公告)日:2012-08-02
The present invention provides a compound of formula (II) where R1 is a substituted alkyl, heterocyclic, or cycloalkyl, group, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof, and pharmaceutical compositions comprising these compounds. Also provided are methods of using these compounds to treat a disease or condition mediated by CDK9, such as cancers and other conditions described herein.